1.Orthogonal experiments for optimizing the formulation and preparation conditions of temozolomide solid lipid nanoparticles.
Mingjin DOU ; Guihua HUANG ; Yanwei XI ; Na ZHANG
Journal of Biomedical Engineering 2008;25(5):1141-1145
TMZ-SLN were prepared by emulsification-low temperature solidification method with stearic acid. The formulation and the preparation conditions were optimized by orthogonal experiments using entrapment efficiency as the evaluation index. The morphology was detected by transmission electron microscope. The Zeta potentials and the particle size distribution were evaluated by Laser Doppler Anemometry. The entrapment efficiencies and the drug release characteristics in vitro were assessed. The result showed that TMZ-SLN were concinnous and spherical in shape. The mean diameter (d(av) ) was 65.0 +/- 6.2 nm and the Zeta potential was -37.2 mV. The average entrapment efficiency was 58.9% +/- 1.21 %. The drug release behavior in vitro conformed to Higuchi Equation. The formation of a new material phase was testified by analysis of differential scanning calorimetry.
Antineoplastic Agents, Alkylating
;
administration & dosage
;
chemistry
;
Dacarbazine
;
administration & dosage
;
analogs & derivatives
;
chemistry
;
Drug Carriers
;
chemistry
;
Lipids
;
chemistry
;
Nanoparticles
;
chemistry
;
Particle Size
;
Stearic Acids
;
chemistry
3.Clinical Result of Prolonged Primary Chemotherapy in Retinoblastoma Patients.
Jeong Hun KIM ; Young Suk YU ; Sang In KHWARG ; Hyoung Soo CHOI ; Hee Young SHIN ; Hyo Seop AHN
Korean Journal of Ophthalmology 2003;17(1):35-43
This study evaluated the effects of prolonged primary chemotherapy in retinoblastoma. The data for 27 eyes in 22 children who were treated for retinoblastoma with up to 13 cycles of primary chemotherapy was reviewed. The chemotherapy consisted of etoposide, vincristine, and either carboplatin or ifosfamide. In bilateral retinoblastoma, 1 eye was in each Ia, Ib, and Va, according to the Reese-Ellsworth classification, 2 in each IIa, IIIa, and IIIb, 4 in IIb, and 5 in IVa. Enucleation was performed in 1 in IIa and 1 in Va. In unilateral, 1 was in each IIa, IIIa, IVa, IVb, and Vb, and 4 in Va. Enucleation was performed in 8 with the exception of 1 in IIa. Complete regression was observed in 17 eyes (12 patients). There was no toxicity severe enough to delay treatment. Prolonged primary chemotherapy can be considered as an alternative treatment for retinoblastoma in III or less.
Antineoplastic Agents/administration& dosage
;
Antineoplastic Agents, Alkylating/administration& dosage
;
Antineoplastic Agents, Phytogenic/administration& dosage
;
Antineoplastic Combined Chemotherapy Protocols/*administration& dosage
;
Carboplatin/administration& dosage
;
Child, Preschool
;
Drug Administration Schedule
;
Etoposide/administration& dosage
;
Eye Enucleation
;
Human
;
Ifosfamide/administration& dosage
;
Infant
;
Retinal Neoplasms/*drug therapy/surgery/ultrasonography
;
Retinoblastoma/*drug therapy/surgery/ultrasonography
;
Retrospective Studies
;
Vincristine/administration& dosage
4.Visual Prognosis of Retinoblastoma in the Posterior Pole Treated with Primary Chemotherapy Plus Local Treatments.
Jae Min KIM ; Jeong Hun KIM ; Seong Joon KIM ; Kyung Duk PARK ; Hee Young SHIN ; Hyo Seop AHN ; Young Suk YU
Korean Journal of Ophthalmology 2010;24(6):347-352
PURPOSE: To evaluate the visual outcomes of retinoblastoma in the posterior pole (RBPP) treated with chemotherapy plus local treatments and to address the prognostic factors that influence such outcomes. METHODS: The medical records of patients with RBPP diagnosed at the Department of Pediatric Ophthalmology, Seoul National University Children's Hospital between August 1987 and September 2007 were reviewed retrospectively. Only those patients treated via primary chemotherapy plus local treatments were included. The presence of foveal involvement and tumors in the posterior pole before and after treatment, the type of regression pattern and the best corrected visual acuity (BCVA) of each patient were evaluated. RESULTS: A total of 13 eyes in 12 patients were included. The mean final BCVA for treated RBPP was 20/210 (range, hand motion to 20/16). However, eight eyes (61.5%) had an acuity of 20/200 or better and seven eyes (53.8%) had an acuity of 20/50 or better. The mean final BCVA was significantly better in cases with negative foveal involvement; however, four eyes (37.5%) with positive foveal involvement had an acuity of 20/200 or better. Tumors area in the posterior pole and the type of regression pattern were not significantly related to final BCVA. CONCLUSIONS: Over one half of the studied RBPP patients had working vision. Although the eyes had RBPP with positive foveal involvement, about one-third of the patients had working vision. Vision preservation should be considered when deciding on RBPP treatment.
Antibiotics, Antineoplastic/administration & dosage
;
Antineoplastic Agents/administration & dosage
;
Antineoplastic Agents, Alkylating/administration & dosage
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Cisplatin/administration & dosage
;
Cyclophosphamide/administration & dosage
;
Doxorubicin/administration & dosage
;
Etoposide/administration & dosage
;
Eyeglasses
;
Female
;
Follow-Up Studies
;
Fovea Centralis/pathology
;
Humans
;
Infant
;
Male
;
Prognosis
;
Retinal Neoplasms/*drug therapy/pathology/*physiopathology
;
Retinoblastoma/*drug therapy/pathology/*physiopathology
;
Retrospective Studies
;
Treatment Outcome
;
Visual Acuity
5.Is the Low-Thalidomide Dose MPT Regimen Beneficial?.
The Korean Journal of Internal Medicine 2011;26(4):400-402
No abstract available.
Angiogenesis Inhibitors/administration & dosage/*therapeutic use
;
Antineoplastic Agents, Alkylating/administration & dosage/*therapeutic use
;
Humans
;
Melphalan/administration & dosage/*therapeutic use
;
Multiple Myeloma/*drug therapy
;
Prednisone/therapeutic use
;
Thalidomide/administration & dosage/*therapeutic use
;
Treatment Outcome
6.Intranasal administration of temozolomide for brain-targeting delivery: therapeutic effect on glioma in rats.
Ying LI ; Yongliang GAO ; Gang LIU ; Xiudi ZHOU ; Yan WANG ; Yulin WANG ; Lin MA
Journal of Southern Medical University 2014;34(5):631-635
OBJECTIVETo study the therapeutic effect of intranasal administration of temozolomide (TMZ) for brain-targeting delivery in a rat model bearing orthotopic C6 glioma xenografts.
METHODSForty Wistar rat bearing brain C6 glioma xenograft were randomly divided into 4 groups and treated with physiological saline solution or with TMZ by intravenous injection, gavage or intranasal administration. The tumor size, rat survival time and pathological changes were observed in each group.
RESULTSMagnetic resonance imaging showed a significantly reduced volume of glioma in intranasal TMZ group compared with that in the control, intraveneous TMZ injection group and TMZ gavage groups (12.45∓2.49 mm(3) vs 60.16∓4.12, 33.17∓3.56, and 35.16∓4.36 mm(3), respectively, P<0.05). The median survival time of the C6 glioma-bearing rats was also significantly longer in intranasal TMZ group than in the other 3 groups (31.0 days vs 20, 19, and 21.5 days, respectively, P<0.05). In the glioma xenografts, PCNA expression was the lowest and tumor cell apoptosis rate the highest in intranasal TMZ group.
CONCLUSIONIntranasal TMZ administration can suppress the growth of C6 glioma in rats and may serve as an effective strategy for glioma treatment.
Administration, Intranasal ; Animals ; Antineoplastic Agents, Alkylating ; administration & dosage ; Apoptosis ; Brain Neoplasms ; drug therapy ; Cell Line, Tumor ; Dacarbazine ; administration & dosage ; analogs & derivatives ; Drug Delivery Systems ; Glioma ; drug therapy ; Magnetic Resonance Imaging ; Neoplasm Transplantation ; Rats ; Rats, Wistar
7.Inhibitory effects of TNP-470 in combination with BCNU on tumor growth of human glioblastoma xenografts.
Dongxiao YAO ; Hongyang ZHAO ; Fangcheng ZHANG ; Jian CHEN ; Xiaobing JIANG ; Xianli ZHU
Journal of Huazhong University of Science and Technology (Medical Sciences) 2010;30(6):757-761
This study investigated the effect of TNP-470 in combination with carmustine (BCNU) on the growth of subcutaneously implanted human glioblastoma xenografts in nude mice. Human glioblastoma U-251 cells (1×10(7)) were injected into 24 nude mice subcutaneously. The tumor-bearing mice were randomly divided into 4 groups on the seventh day following tumor implantation: TNP-470 group, in which TNP-470 was given 30 mg/kg subcutaneously every other day 7 times; BCNU group, in which 20 mg/kg BCNU were injected into peritoneal cavity per 4 days 3 times; TNP-470 plus BCNU group, in which TNP-470 and BCNU were coadministered in the same manner as in the TNP-470 group and the BCNU group; control group, in which the mice were given 0.2 mL of the mixture including 3% ethanol, 5% acacia and 0.9% saline subcutaneously every other day 7 times. The tumor size and weights were measured. The tumor microvessel density (MVD) was determined by immunostaining by using goat-anti-mouse polyclonal antibody CD105. The results showed that on the 21th day following treatment, the volume of xenografts in the TNP-470 plus BCNU group was (108.93±17.63)mm(3), markedly lower than that in the TNP-470 group [(576.10±114.29)mm(3)] and the BCNU group [(473.01±48.04)mm(3)] (both P<0.01). And the xenograft volume in these 3 treatment groups was even much lower than that in the control group [(1512.61±470.25) mm(3)] (all P<0.01). There was no significant difference in the volume of xenografts between the TNP-470 group and the BCNU group (P>0.05). The inhibition rate of the tumor growth in the TNP-470 plus BCNU group was (92.80±11.37)%, notably higher than that in the TNP-470 group [(61.91±6.29)%] and the BCNU group [(68.73±9.65)%] (both P<0.01) on the 21th day following treatment. There was no significant difference in the inhibition rate of tumor growth between the TNP-470 group and the BCNU group (P>0.05). The MVD of xenografts in the TNP-470 plus BCNU group was decreased significantly as compared with that in the TNP-470 group or the BCNU group (both P<0.05). The MVD of xenografts in the 3 treatment groups was markedly reduced as compared with that in the control group (all P<0.05). No significant changes in weights were observed before and after the treatment in each group (all P>0.05). It was concluded that the combination of TNP-470 and BCNU can significantly inhibit the growth of human glioblastoma xenografts in nude mice without evident side effects.
Angiogenesis Inhibitors
;
administration & dosage
;
Animals
;
Antibiotics, Antineoplastic
;
administration & dosage
;
Antineoplastic Agents, Alkylating
;
administration & dosage
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Brain Neoplasms
;
drug therapy
;
Carmustine
;
administration & dosage
;
Cell Line, Tumor
;
Cyclohexanes
;
administration & dosage
;
Female
;
Glioblastoma
;
drug therapy
;
Humans
;
Mice
;
Mice, Inbred BALB C
;
Mice, Nude
;
Sesquiterpenes
;
administration & dosage
;
Xenograft Model Antitumor Assays
8.Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy.
Michael F BACK ; Emily L L ANG ; Wai-Hoe NG ; Siew-Ju SEE ; C C Tchoyoson LIM ; S P CHAN ; Tseng-Tsai YEO
Annals of the Academy of Medicine, Singapore 2007;36(5):338-342
INTRODUCTIONThe use of adjuvant temozolomide (TMZ) in patients managed with surgery and adjuvant radiation therapy (RT) for glioblastoma multiforme (GBM) has been demonstrated to improve median and 2-year survival in a recent large international multicentre study. To confirm this result in routine clinical practice, an audit of the management and outcome of patients with GBM at The Cancer Institute Radiation Oncology was performed.
MATERIALS AND METHODSAll patients with GBM managed radically at The Cancer Institute Radiation Oncology from May 2002 to 2006 were entered into a prospective database. Patient, tumour and treatment factors were analysed for association with the outcome of median survival (MS). Survival was calculated using the Kaplan-Meier technique and correlation was assessed using Cox proportional hazards regression.
RESULTSForty-one patients with GBM were managed with radical intent over the 4- year period. The median age was 54 years and 66% were Eastern Cooperative Oncology Group (ECOG) 0-1 performance status. Macroscopic, subtotal and biopsy alone procedures were performed in 61%, 29% and 10% of patients, respectively. The median time from surgery to RT was 26 days. Adjuvant TMZ was used in 44% of patients (n = 18). The MS of the total group was 13.6 months, with a 24% 2-year overall survival. The use of TMZ was associated with improved MS (19.6 versus 12.8 months; P = 0.035) and improved 2-year survival (43% versus 0%). A requirement of dexamethasone dose greater than 4 mg at the end of RT (P = 0.012) was associated with worse survival, but there was no association of MS with age, ECOG, tumour size or extent of surgery.
CONCLUSIONThe median and 2-year survival outcomes are comparable to the results of the European Multicentre Study and justify the continued use of TMZ in routine clinical practice.
Antineoplastic Agents, Alkylating ; administration & dosage ; therapeutic use ; Brain Neoplasms ; drug therapy ; radiotherapy ; surgery ; Chemotherapy, Adjuvant ; Dacarbazine ; administration & dosage ; analogs & derivatives ; therapeutic use ; Female ; Glioblastoma ; drug therapy ; radiotherapy ; surgery ; Humans ; Male ; Middle Aged ; Prospective Studies ; Singapore ; Survival Analysis
9.Application of
Jing Hui YANG ; Fan Zhu MENG ; Cheryl L BESELER ; Hao LI ; Xiao Mei LIU ; Yin Pei GUO ; Li Li QIN ; Ru Yue ZUO ; Shu Ping REN
Biomedical and Environmental Sciences 2021;34(12):1010-1014
10.Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
José Antonio LÓPEZ-GUERRERO ; Ignacio ROMERO ; Andrés POVEDA
Chinese Journal of Cancer 2015;34(1):41-49
Epithelial ovarian cancer (OC) is a common gynecologic malignancy in women. The standard treatment for OC is maximal cytoreductive surgical debulking followed by platinum-based chemotherapy. Despite the high response rate to primary therapy, approximately 85% of patients will develop recurrent ovarian cancer (ROC). This review identifies the clinical use of trabectedin in the treatment algorithm for ROC, with specific emphasis on platinum-sensitive ROC, for which trabectedin in combination with pegylated liposomal doxorubicin has been approved as a treatment protocol. The main mechanisms of action of trabectedin at the cellular level and in the tumor microenvironment is also discussed as bases for identifying biomarkers for selecting patients who may largely benefit from trabectedin-based therapies.
Antineoplastic Agents, Alkylating
;
therapeutic use
;
Clinical Trials as Topic
;
DNA Damage
;
Dioxoles
;
administration & dosage
;
pharmacology
;
therapeutic use
;
Doxorubicin
;
administration & dosage
;
analogs & derivatives
;
Female
;
Humans
;
Neoplasm Recurrence, Local
;
drug therapy
;
Neoplasms, Glandular and Epithelial
;
drug therapy
;
Ovarian Neoplasms
;
drug therapy
;
Polyethylene Glycols
;
administration & dosage
;
Tetrahydroisoquinolines
;
administration & dosage
;
pharmacology
;
therapeutic use
;
Tumor Microenvironment